Abbott On Track To Reach U.S. DES Market By Late 2007 With ZoMaxx
This article was originally published in The Gray Sheet
Executive Summary
Abbott is counting on the deliverability of its ZoMaxx ABT-578-eluting stent to differentiate it from established competitors in the U.S. market
You may also be interested in...
J&J/Guidant Will Share RX Stent Delivery With Abbott If Guidant Deal Closes
Abbott could be a strong player in the drug-eluting stent market by 2007 if the J&J/Guidant merger is completed as required by FTC
J&J/Guidant Will Share RX Stent Delivery With Abbott If Guidant Deal Closes
Abbott could be a strong player in the drug-eluting stent market by 2007 if the J&J/Guidant merger is completed as required by FTC
Abbott Vascular Ripens With Anticipated 2005 Launches Of Stent, Sealant
Rapid hospital discharges associated with Abbott's StarClose will favor the device over manual femoral access closure methods upon launch in the second half of 2005, the firm claims